Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 Weeks
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Beloranib (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Zafgen
- 08 May 2015 According to Zafgen media release, results presented at the 22nd European Congress on Obesity (ECO).
- 08 May 2015 Results published in the Zafgen media release.
- 18 Nov 2013 According to a Zafgen media release, final efficacy and safety data of this trial were presented for the first time at Obesity Week 2013 on 15 November.